SUPPLEMENTAL MATERIAL

Figure 3a. Median weight over time after ART initiation by region



Figure 3b. Median weight gain at 6, 12, 18, 24 months of ART by region



We used these plots to assess the homogeneity of weight gains across regions before deciding whether to merge them. Abbreviations: CA = Central Africa, EA = Eastern Africa, SA = Southern Africa, WA = West Africa

Table 3. Parameters estimates from a quantile regression model of change in weight over time and assessing how this change varies by region

Parameter		DF	Estimate	Standard Error	95% confidence Interval		t Value	Pr > |t|
Intercept		1	21.166	1.7562	17.7233	24.6087	12.05	<.0001
time		1	0.0114	0.002	0.0075	0.0153	5.74	<.0001
region	1	1	-1.8121	1.9261	-5.5878	1.9635	-0.94	0.3468
region	2	1	10.5152	6.8435	-2.9001	23.9304	1.54	0.1245
region	3	1	2.1814	1.839	-1.4237	5.7864	1.19	0.2356
region	4	1	1.1603	1.8129	-2.3935	4.7142	0.64	0.5222
region	5	0	0	0	0	0	.	.
time*region	1	1	0.001	0.0021	-0.0031	0.0051	0.47	0.6351
time*region	2	1	-0.0062	0.0052	-0.0164	0.0039	-1.21	0.2275
time*region	3	1	-0.0027	0.0021	-0.0069	0.0015	-1.26	0.2071
time*region	4	1	-0.0023	0.0021	-0.0063	0.0017	-1.11	0.2652
time*region	5	0	0	0	0	0	.	.

Region: 1 = Asia, 2 = Central Africa, 3 = Eastern Africa, 4 = Southern Africa, 5 = West Africa

The none of the interaction term between whether the slope of change in weight by time on ART differ across region is statistically significant confirming the observation of homogeneity of weight gain across region from figures 3a and 3b above.

Table 4a. Characteristics at antiretroviral therapy (ART) initiation of 5029 children < 10 years of age included in the analysis of 12-month weight gain

	Overall		Asia-Pacific		Central Africa		East Africa		Southern Africa		West Africa	
Characteristics	Number**	Percentage	Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage
Sex												
Male	2606	51.82	386	51.06	126	49.61	567	53.04	1278	51.04	249	55.83
Female	2423	48.18	370	48.94	128	50.39	502	46.96	1226	48.96	197	44.17
CD4%												
<15%	2727	75.23	482	78.25	2	50.0	520	81.50	1505	73.49	218	68.34
15-25 %	716	19.75	117	18.99	2	50.0	93	14.58	429	20.95	75	23.51
> 25%	182	5.02	17	2.76	0	-	25	3.92	114	5.57	26	8.15
Viral load												
>=100 000 copies/ml	629	35.26	89	28.95	0	-	0	-	533	37.09	8	18.6
<100000 copies/ml	1155	64.74	216	71.05	0	-	0	-	904	62.91	35	81.4
Weight-for-age Z-score†												
≥-1SD	1390	27.95	156	20.97	56	22.31	308	29.08	756	30.55	114	25.68
<-1 to ≥-2SD	1372	27.59	170	22.85	71	28.29	302	28.52	705	28.48	124	27.93
<-2 to ≥-3SD	1052	21.15	176	23.66	51	20.32	241	22.76	487	19.68	97	21.85
< -3SD	1159	23.31	242	32.53	73	29.08	208	19.64	527	21.29	109	24.55
Age at ART initiation												
0-1	1126	22.39	86	11.38	53	20.87	154	14.41	730	29.15	103	23.09
2-4	1869	37.16	273	36.11	90	35.43	431	40.32	898	35.86	177	39.69
5-9	2034	40.45	397	52.51	111	43.70	484	45.28	876	34.98	166	37.22
Year of ART initiation												
2003	222	4.41	133	17.59	0	-	0	-	89	3.55	0	-
2004	718	14.28	54	7.14	14	5.51	85	7.95	479	19.13	86	19.28
2005	1623	32.27	140	18.52	87	34.25	256	23.95	922	36.82	218	48.88
2006	1612	32.05	228	30.16	77	30.31	457	42.75	748	29.87	102	22.87
2007	631	12.55	125	16.53	48	18.90	271	25.35	150	5.99	37	8.30
2008	220	4.37	74	9.79	28	11.02	0	-	115	4.59	3	0.67
2009	3	0.06	2	0.26	0	-	0	-	1	0.04	0	-
Time on ART in months [median (IQR)]	5029	‡	756	45.6 (34.6, 57.9)	254	43.3 (29.2, 48.3)	1069	26.4 (19.5, 33.7)	2504	26.0 (19.5, 33.6)	446	30.5 (23.0, 38.1)

*Children were included if they had at least 12 months of follow-up on ART and at least a pre-ART and a 12-month measurement needed to estimate the 12-month weight gain. IQR = interquartile range. †Sex-specific weight- and height- for-age Z scores were obtained by plotting the weight measurements at baseline against the WHO weight- and height-for-age charts. ‡ Minimum = 12 months, Maximum = 59 months.
**Totals vary by baseline characteristics due to missing data

Table 4b. Characteristics at antiretroviral therapy (ART) initiation of 4288 children <10 years of age included in the analysis of 18-month weight gain

	Overall		Asia-Pacific		Central Africa		East Africa		Southern Africa		West Africa	
Characteristics	Number**	Percentage	Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage
Sex												
Male	2232	52.05	376	52.08	115	49.36	447	51.44	1070	52.27	224	53.72
Female	2056	47.95	346	47.92	118	50.64	422	48.56	977	47.73	193	46.28
CD4%												
<15%	2331	75.53	456	76.90	2	50.0	413	81.14	1257	74.96	203	67.00
15-25 %	602	19.51	114	19.22	2	50.0	74	14.54	336	20.04	76	25.08
> 25%	153	4.96	23	3.88			22	4.32	84	5.01	24	7.92
Viral load												
>=100,000 copies/ml	501	34.01	94	31.02	0	-	0	-	398	35.16	9	23.68
<100,000 copies/ml	972	65.99	209	68.98	0	-	0	-	734	64.84	29	76.32
Weight-for-age Z=score†												
≥-1SD	1176	27.76	153	21.55	52	22.61	248	28.80	616	30.48	107	25.85
<-1 to ≥-2SD	1181	27.88	169	23.80	64	27.83	243	28.22	585	28.95	120	28.99
<-2 to ≥-3SD	889	20.99	161	22.68	47	20.43	200	23.23	397	19.64	84	20.29
< -3SD	990	23.37	227	31.97	67	29.13	170	19.74	423	20.93	103	24.88
Age at ART initiation												
0-1	954	22.25	89	12.33	52	22.32	121	13.92	592	29.16	95	22.78
2-4	1693	39.48	289	40.03	87	37.34	378	43.50	765	37.37	174	41.73
5-9	1641	38.27	344	47.65	94	40.34	370	42.58	685	33.46	148	35.49
Year of ART iInitiation												
2003	190	4.43	107	14.82	0	-	0	-	83	4.05	0	-
2004	655	15.28	51	7.06	14	6.01	83	9.55	429	20.96	78	18.71
2005	1547	36.08	132	18.28	86	36.91	246	28.31	873	42.65	210	50.36
2006	1324	30.88	220	30.47	75	32.19	442	50.86	488	23.84	99	23.74
2007	418	9.75	144	19.94	46	19.74	98	11.28	100	4.89	30	7.19
2008	154	3.59	68	9.42	12	5.15	0	-	74	3.62	0	-
Time on ART in months]median (IQR)]	4288	30.7 (24.1, 40.0)	722	44.9 (33.3, 56.2)	233	43.7 (29.8, 49.2)	869	27.8 (23.3, 34.9)	2047	28.8 (22.9, 34.8)	417	31.0 (24.2, 38.6)

*Children were included if they had at least 18 months of follow-up on ART and at least a pre-ART and a 18-month measurement needed to estimate the 18-month gain. IQR = interquartile range. †Sex-specific weight- and height- for-age z scores were obtained by plotting the weight measurements at baseline against the World Health Organization (WHO) weight- and height-for-age charts. ‡ Minimum = 18 months, Maximum = 59 months. **Totals vary by baseline characteristics due to missing data.

Table 4c. Characteristics at antiretroviral therapy (ART) initiation of 3072 children <10 years of age included in the analysis of 24-month weight gain

	Overall		Asia		Central Africa		East Africa		Southern Africa		West Africa	
Characteristics	Number**	Percentage	Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage
Sex												
Male	1607	52.31	310	52.28	97	50.52	301	51.37	741	52.93	158	52.49
Female	1465	47.69	283	47.72	95	49.48	285	48.63	659	47.07	143	47.51
CD4%												
<15%	1637	75.54	360	75.16	1	33.33	265	81.79	861	76.33	150	64.38
15-25 %	417	19.24	98	20.46	2	66.67	45	13.89	214	18.97	58	24.89
>25%	113	5.21	21	4.38	0	-	14	4.32	53	4.70	25	10.73
Viral load												
>=100,000 copies/ml	335	32.71	77	32.91	0	-	0	-	250	32.72	8	30.77
<100,000 copies/ml	680	67.29	157	67.09	0	-	0	-	514	67.28	18	69.23
Weight-for-age Z-score†												
≥-1SD	854	28.18	128	21.99	40	21.16	177	30.41	431	31.23	78	26.17
<-1 to ≥-2SD	794	26.20	130	22.34	50	26.46	144	24.74	383	27.75	87	29.19
<-2 to ≥-3SD	640	21.12	130	22.34	39	20.63	133	22.85	274	19.86	64	21.48
< -3SD	743	24.51	194	33.33	60	31.75	128	21.99	292	21.16	69	23.15
Age at ART initiation (years)												
0-1	627	20.41	80	13.49	47	24.48	78	13.31	354	25.29	68	22.59
2-4	1317	42.87	241	40.64	77	40.10	269	45.90	585	41.79	145	48.17
5-9	1128	36.72	272	45.87	68	35.42	239	40.78	461	32.93	88	29.24
Year of ART initiation												
2003	151	4.92	77	12.98	0	-	0	-	74	5.29	0	-
2004	562	18.29	43	7.25	12	6.25	75	12.80	364	26.00	68	22.59
2005	1317	42.87	131	22.09	78	40.63	226	38.57	723	51.64	159	52.82
Time on ART in months [median (IQR)]	3072	34.2 (28.7, 42.8)	593	45.6 (37.6, 55.9)	192	44.3 (38.2, 50.1)	586	31.9 (27.3, 39.0)	1400	32.3 (28.2, 37.7)	301	33.7 (28.7, 40.3)

*Children were included if they had at least 24 months of follow-up on ART and at least a pre-ART and a 24-month measurement needed to estimate the 24-month gain. IQR = interquartile range. †Sex-specific weight- and height- for-age z scores were obtained by plotting the weight measurements at baseline against the World Health Organization (WHO) weight- and height-for-age charts. ‡ Minimum = 24 months, Maximum = 59 months. **Totals vary by baseline characteristics due to missing data

Table 5. Distribution of outcomes by lower centile of weight gain at 6-, 12-, 28-, and 24-months

	Deaths		Virologic suppression		Virologic failure		Deaths		Virologic suppression		Virologic failure	
	Total	Events	Total	Events	Total	Events	Total	Events	Total	Events	Total	Events
	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)
Percentile	**Weight gain at 6 month after ART initiation**						**Weight gain at 18 months after ART initiation**					
3rd												
No	6946	92 (1.32)	3248	2109 (64.93)	1295	547 (42.24)	4136	23 (0.56)	2098	1581 (75.36)	1030	417 (40.49)
Yes	227	19 (8.37)	68	39 (57.35)	23	11 (47.83)	152	-	65	47 (72.31)	31	9 (29.03)
10th												
No	6604	74 (1.12)	3127	2032 (64.98)	1256	531 (42.28)	3880	20 (0.52)	1983	1488 (75.04)	970	396 (40.82)
Yes	569	37 (6.50)	189	116 (61.38)	62	27 (43.55)	408	3 (0.74)	180	140 (77.78)	91	30 (32.97)
25th												
No	5422	56 (1.03)	2606	1680 (64.47)	1043	438 (41.99)	3205	14 (0.44)	1640	1227 (74.82)	814	334 (41.03)
Yes	1751	55 (3.14)	710	468 (65.92)	275	120 (43.64)	1083	9 (0.83)	523	401 (76.67)	247	92 (37.25)
33rd												
No	4778	52 (1.09)	2297	1462 (63.65)	918	390 (42.48)	2853	13 (0.46)	1448	1085 (74.93)	720	296 (41.11)
Yes	2395	59 (2.46)	1019	682 (67.32)	400	168 (42.00)	1435	10 (0.70)	715	543 (75.94)	341	130 (38.12)
50th												
No	3531	44 (1.25)	1699	1055 (62.10)	644	272 (42.24)	2111	8 (0.38)	1060	801 (75.57)	520	212 (40.77)
Yes	3642	67 (1.84)	1617	1093 (67.59)	674	286 (42.43)	2177	15 (0.69)	1103	827 (74.98)	541	214 (39.56)
	Weight gain at 12 months after ART initiation						**Weight gain at 24 months after ART initiation**					
3rd												
No	4845	36 (0.74)	2354	1727 (73.36)	1149	484 (42.12)	2959	10 (0.34)	1567	1205 (76.90)	800	321 (40.13)
Yes	184	7 (3.80)	72	53 (73.61)	28	11 (39.29)	113	1 (0.88)	58	39 (67.24)	34	15 (44.12)
10th												
No	4570	33 (0.72)	2235	1645 (73.60)	1095	464 (42.37)	2768	9 (0.33)	1479	1133 (76.61)	755	304 (40.26)
Yes	459	10 (2.18)	191	135 (70.68)	82	31 (37.80)	304	2 (0.66)	146	111 (76.03)	79	32 (40.51)
25th												
No	3750	27 (0.72)	1856	1359 (73.22)	908	388 (42.73)	2317	5 (0.22)	1237	948 (76.64)	640	257 (40.16)
Yes	1279	16 (1.25)	570	421 (73.86)	269	107 (39.78)	755	6 (0.79)	388	296 (76.29)	194	79 (40.72)
33rd												
No	3300	22 (0.67)	1626	1197 (73.62)	808	345 (42.70)	2053	3 (0.15)	1098	842 (76.68)	571	233 (40.81)
Yes	1729	21 (1.21)	800	583 (72.88)	369	150 (40.65)	1019	8 (0.79)	527	402 (76.28)	263	103 (39.16)
50th												
No	2493	18 (0.72)	1227	897 (73.11)	600	264 (44.00)	1545	2 (0.13)	822	630 (76.64)	431	180 (41.76)
Yes	2536	27 (0.99)	1199	883 (73.64)	577	231 (40.03)	1527	9 (0.59)	803	614 (76.46)	403	156 (38.71)

Table 6a. Centile distribution of weight gain at 6 months after ART initiation

Current age in months	Centile distribution of weight gain at 6 months after ART initiation								
	Males								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
6	0.74	1.53	2.35	2.67	3.26	3.87	4.19	5.05	5.91
12	0.37	1.07	1.77	2.04	2.54	3.05	3.33	4.10	4.91
18	0.12	0.75	1.38	1.62	2.05	2.50	2.75	3.47	4.25
24	0.02	0.62	1.21	1.43	1.83	2.24	2.48	3.19	4.00
30	-0.03	0.56	1.13	1.34	1.72	2.11	2.34	3.05	3.91
36	-0.11	0.47	1.02	1.22	1.57	1.93	2.16	2.86	3.74
42	-0.20	0.36	0.90	1.09	1.41	1.75	1.97	2.66	3.55
48	-0.26	0.30	0.83	1.02	1.33	1.65	1.86	2.54	3.45
54	-0.30	0.28	0.81	0.99	1.29	1.61	1.82	2.50	3.42
60	-0.31	0.28	0.82	1.00	1.31	1.63	1.83	2.53	3.46
66	-0.31	0.31	0.87	1.06	1.36	1.69	1.90	2.61	3.57
72	-0.32	0.32	0.90	1.10	1.41	1.74	1.96	2.68	3.66
78	-0.35	0.31	0.90	1.10	1.42	1.75	1.96	2.69	3.68
84	-0.38	0.29	0.89	1.09	1.41	1.75	1.97	2.71	3.70
90	-0.37	0.32	0.93	1.14	1.48	1.83	2.06	2.82	3.83
96	-0.36	0.35	0·99	1.21	1.57	1.94	2.19	2.97	4.00
102	-0.37	0.34	1.00	1.23	1.61	2.00	2.25	3.05	4.08
108	-0.41	0.29	0.96	1.19	1.59	2.00	2.26	3.06	4.06
114	-0.46	0.24	0.92	1.16	1.57	2.00	2.27	3.06	4.03
120	-0.51	0.21	0.90	1.15	1.59	2.04	2.31	3.11	4.04

Table 6b. Centile distribution of weight gain at 6 months after ART initiation

Current age in months	Centile distribution of weight gain at 6 months after ART initiation								
	Females								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
6	0.77	1.60	2.38	2.67	3.16	3.66	3.96	4.82	5.82
12	0.40	1.15	1.85	2.10	2.53	2.97	3.24	4.02	4.95
18	0.06	0.74	1.36	1.58	1.95	2.33	2.56	3.27	4.12
24	-0.07	0.59	1.19	1.40	1.75	2.11	2.34	3.03	3.88
30	-0.13	0.53	1.13	1.34	1.68	2.04	2.26	2.96	3.83
36	-0.22	0.42	1.00	1.20	1.54	1.88	2.10	2.79	3.66
42	-0.30	0.34	0.91	1.11	1.43	1.76	1.98	2.67	3.55
48	-0.41	0.20	0.76	0.94	1.25	1.56	1.77	2.44	3.31
54	-0.45	0.16	0.71	0.90	1.20	1.52	1.72	2.39	3.29
60	-0.46	0.17	0.74	0.93	1.25	1.57	1.78	2.48	3.40
66	-0.42	0.24	0.84	1.04	1.38	1.73	1.96	2.70	3.67
72	-0.42	0.25	0.88	1.09	1.44	1.81	2.05	2.81	3.81
78	-0.45	0.23	0.86	1.08	1.45	1.83	2.07	2.85	3.85
84	-0.50	0.19	0.83	1.05	1.43	1.82	2.06	2.85	3.84
90	-0.50	0.22	0.89	1.12	1.51	1.92	2.18	2.99	4.02
96	-0.52	0.23	0.93	1.17	1.58	2.01	2.27	3.11	4.16
102	-0.53	0.24	0.97	1.22	1.65	2.10	2.37	3.24	4.31
108	-0.58	0.20	0.94	1.20	1.64	2.09	2.37	3.24	4.32
114	-0.59	0.23	1.01	1.28	1.74	2.21	2.51	3.41	4.52
120	-0.53	0.38	1.24	1.54	2.05	2.57	2.89	3.88	5.09

Table 7a. Centile distribution of weight gain at 12 months after ART initiation

Current age in months	Centile distribution of weight gain at 12 months after ART initiation								
	Males								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
12	1.02	2.26	3.43	3.85	4.57	5.30	5.73	6.95	8.33
18	0.89	1.99	3.05	3.42	4.09	4.76	5.16	6.32	7.64
24	0.77	1.75	2.70	3.04	3.64	4.27	4.64	5.73	7.01
30	0.68	1.55	2.41	2.72	3.28	3.86	4.21	5.25	6.49
36	0.61	1.39	2.18	2.47	2.99	3.53	3.87	4.87	6.09
42	0.55	1.27	2.00	2.27	2.76	3.28	3.60	4.57	5.77
48	0.50	1.17	1.87	2.13	2.60	3.10	3.41	4.36	5.56
54	0.47	1.12	1.79	2.05	2.51	3.00	3.30	4.25	5.45
60	0.46	1.10	1.77	2.02	2.48	2.97	3.27	4.23	5.45
66	0.45	1.10	1.78	2.04	2.50	2.99	3.30	4.28	5.52
72	0.45	1.12	1.81	2.07	2.54	3.05	3.36	4.35	5.62
78	0.45	1.13	1.84	2.10	2.58	3.10	3.42	4.43	5.71
84	0.44	1.14	1.87	2.14	2.63	3.16	3.48	4.51	5.80
90	0.44	1.17	1.92	2.20	2.70	3.24	3.58	4.62	5.94
96	0.45	1.20	1.99	2.28	2.80	3.36	3.71	4.78	6.13
102	0.46	1.25	2.07	2.37	2.92	3.50	3.86	4.96	6.34
108	0.45	1.28	2.13	2.45	3.02	3.62	3.98	5.12	6.51
114	0.44	1.30	2.18	2.51	3.09	3.71	4.08	5.24	6.64
120	0.42	1.31	2.22	2.56	3.16	3.79	4.17	5.34	6.76

Table 7b. Centile distribution of weight gain at 12 months after ART initiation

Current age in months	Centile distribution of weight gain at 12 months after ART initiation								
	Females								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
12	1.27	2.47	3.58	3.97	4.63	5.31	5.71	6.89	8.26
18	1.06	2.14	3.15	3.51	4.13	4.76	5.13	6.25	7.56
24	0.87	1.83	2.74	3.07	3.64	4.23	4.58	5.63	6.87
30	0.72	1.58	2.43	2.73	3.27	3.82	4.16	5.16	6.36
36	0.62	1.41	2.21	2.50	3.01	3.55	3.87	4.86	6.03
42	0.54	1.28	2.04	2.31	2.81	3.34	3.66	4.63	5.80
48	0.47	1.16	1.88	2.15	2.63	3.15	3.46	4.42	5.59
54	0.41	1.06	1.74	2.00	2.48	2.98	3.29	4.24	5.41
60	0.37	1.01	1.68	1.94	2.41	2.92	3.23	4.20	5.39
66	0.38	1.02	1.70	1.96	2.45	2.97	3.30	4.29	5.54
72	0.40	1.05	1.76	2.04	2.55	3.10	3.43	4.48	5.79
78	0.41	1.10	1.84	2.13	2.66	3.23	3.59	4.69	6.06
84	0.42	1.13	1.90	2.20	2.76	3.36	3.73	4.87	6.30
90	0.43	1.16	1.96	2.27	2.85	3.48	3.86	5.05	6.52
96	0.44	1.20	2.04	2.36	2.97	3.62	4.02	5.25	6.79
102	0.45	1.25	2.12	2.46	3.09	3.77	4.19	5.47	7.07
108	0.45	1.27	2.17	2.52	3.17	3.88	4.31	5.64	7.29
114	0.44	1.27	2.18	2.54	3.20	3.92	4.36	5.72	7.40
120	0.41	1.25	2.18	2.54	3.21	3.94	4.39	5.77	7.47

Table 8a. Centile distribution of weight gain at 18 months after ART initiation

Current age in months	Centile distribution of weight gain at 18 months after ART initiation								
	Males								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
18	1.82	3.20	4.50	4.98	5.81	6.64	7.10	8.33	9.60
24	1.66	2.90	4.08	4.52	5.29	6.07	6.50	7.67	8.91
30	1.53	2.64	3.73	4.12	4.84	5.57	5.98	7.11	8.33
36	1.43	2.43	3.42	3.79	4.46	5.15	5.54	6.64	7.85
42	1.32	2.21	3.11	3.45	4.07	4.72	5.09	6.16	7.35
48	1.23	2.04	2.87	3.19	3.77	4.39	4.75	5.79	6.98
54	1.18	1.94	2.73	3.03	3.59	4.19	4.54	5.58	6.79
60	1.15	1.88	2.65	2.95	3.50	4.08	4.43	5.48	6.72
66	1.16	1.89	2.66	2.96	3.51	4.10	4.46	5.53	6.83
72	1.19	1.93	2.72	3.02	3.58	4.19	4.55	5.67	7.02
78	1.22	1.99	2.80	3.12	3.69	4.31	4.69	5.84	7.24
84	1.20	2.00	2.84	3.16	3.74	4.37	4.75	5.91	7.34
90	1.14	1.98	2.84	3.16	3.75	4.38	4.76	5.92	7.33
96	1.10	2.00	2.90	3.24	3.84	4.47	4.85	6.03	7.45
102	1.07	2.05	3.00	3.36	3.97	4.62	5.01	6.21	7.65
108	1.04	2.12	3.16	3.53	4.17	4.84	5.24	6.46	7.92
114	0.98	2.16	3.27	3.66	4.32	5.00	5.42	6.64	8.10
120	0.90	2.16	3.33	3.73	4.41	5.09	5.50	6.72	8.14

Table 8b. Centile distribution of weight gain at 18 months after ART initiation

Current age in months	Centile distribution of weight gain at 18 months after ART initiation								
	Females								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
18	1.75	3.29	4.66	5.13	5.92	6.69	7.12	8.29	9.51
24	1.57	2.94	4.18	4.61	5.36	6.09	6.51	7.65	8.87
30	1.44	2.63	3.74	4.14	4.83	5.53	5.93	7.04	8.25
36	1.33	2.38	3.39	3.75	4.41	5.07	5.45	6.55	7.76
42	1.27	2.20	3.13	3.47	4.09	4.74	5.11	6.20	7.44
48	1.21	2.06	2.92	3.25	3.84	4.47	4.84	5.94	7.20
54	1.13	1.91	2.72	3.04	3.61	4.23	4.59	5.68	6.95
60	1.02	1.78	2.57	2.87	3.44	4.04	4.40	5.47	6.73
66	0.97	1.72	2.51	2.82	3.39	3.99	4.35	5.43	6.70
72	0.97	1.74	2.56	2.88	3.47	4.09	4.47	5.58	6.90
78	0.98	1.81	2.68	3.01	3.63	4.29	4.68	5.85	7.22
84	0.99	1.88	2.81	3.16	3.82	4.52	4.93	6.14	7.56
90	0.96	1.92	2.91	3.29	3.98	4.71	5.14	6.39	7.82
96	0.90	1.93	2.98	3.38	4.10	4.85	5.29	6.56	8.00
102	0.84	1.93	3.04	3.46	4.21	4.99	5.44	6.73	8.18
108	0.85	1.97	3.11	3.54	4.32	5.13	5.60	6.94	8.45
114	0.91	2.02	3.18	3.63	4.43	5.28	5.77	7.19	8.79
120	0.99	2.09	3.26	3.71	4.54	5.42	5.93	7.44	9.16

Table 9a. Centile distribution of weight gain at 24 months after ART initiation

Current age in months	Centile distribution of weight gain at 24 months after ART initiation								
	Males								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
24	3.60	4.53	5.52	5.91	6.67	7.45	7.86	8.93	9.99
30	3.24	4.15	5.11	5.50	6.25	7.01	7.42	8.49	9.57
36	2.89	3.78	4.72	5.10	5.82	6.57	6.98	8.05	9.15
42	2.57	3.43	4.35	4.71	5.41	6.14	6.54	7.61	8.72
48	2.27	3.10	3.99	4.34	5.01	5.72	6.11	7.17	8.29
54	2.02	2.82	3.68	4.02	4.68	5.36	5.74	6.79	7.91
60	1.83	2.64	3.50	3.84	4.48	5.15	5.53	6.59	7.73
66	1.72	2.55	3.43	3.78	4.43	5.11	5.49	6.57	7.75
72	1.68	2.55	3.46	3.82	4.48	5.17	5.57	6.69	7.92
78	1.65	2.57	3.52	3.89	4.56	5.27	5.67	6.82	8.10
84	1.66	2.62	3.61	3.99	4.68	5.39	5.80	6.98	8.29
90	1.68	2.68	3.70	4.08	4.77	5.49	5.90	7.09	8.43
96	1.70	2.74	3.77	4.16	4.85	5.56	5.97	7.16	8.50
102	1.75	2.83	3.88	4.26	4.95	5.65	6.07	7.26	8.61
108	1.83	2.94	4.02	4.40	5.09	5.79	6.21	7.40	8.76
114	1.93	3.10	4.20	4.60	5.29	5.99	6.41	7.62	9.01
120	2.05	3.27	4.41	4.82	5.52	6.23	6.65	7.89	9.31

Table 9b. Centile distribution of weight gain at 24 months after ART initiation

Current age in months	Centile distribution of weight gain at 24 months after ART initiation								
	Females								
	c3	c10	c25	C33	c50	c67	c77	c90	c97
24	3.38	4.51	5.60	6.00	6.72	7.44	7.84	8.92	10.03
30	3.03	4.11	5,16	5.55	6.25	6.96	7.36	8.42	9.53
36	2.70	3.72	4.72	5.10	5.79	6.49	6.87	7.92	9.03
42	2.40	3.36	4.33	4.69	5.37	6.05	6.43	7.47	8.58
48	2.14	3.06	4.00	4.35	5.02	5.70	6.07	7.12	8.23
54	1.92	2.81	3.72	4.07	4.73	5.40	5.78	6.83	7.95
60	1.75	2.60	3.49	3.84	4.48	5.15	5.53	6.58	7.70
66	1.64	2.47	3.35	3.69	4.34	5.01	5.39	6.44	7.57
72	1.61	2.45	3.34	3.68	4.34	5.02	5.41	6.48	7.65
78	1.63	2.50	3.42	3.78	4.47	5.17	5.57	6.68	7.88
84	1.69	2.61	3.57	3.95	4.66	5.40	5.81	6.96	8.19
90	1.76	2.72	3.73	4.12	4.86	5.62	6.05	7.22	8.46
96	1.82	2.83	3.87	4.28	5.04	5.82	6.25	7.43	8.68
102	1.87	2.92	4.01	4.42	5.20	6.00	6.44	7.63	8.87
108	1.91	3.01	4.13	4.56	5.36	6.17	6.62	7.81	9.05
114	1.95	3.09	4.24	4.68	5.49	6.32	6.76	7.96	9.19
120	1.99	3.16	4.34	4.78	5.61	6.44	6.89	8.09	9.31

LIST OF IeDEA INVESTIGATORS

The Central Africa IeDEA Pediatric Working Group (2006-2011) includes: Dr. Théodore Niyongabo, Dr. Helene Bukuru, Dr Martin Nduwimana, and Dr. Pierre Kariyo of Centre Hospitalo-Universitaire de Kamenge, Bujumbura Burundi; Dr. Marcel Mbaya, Dr. Henri Mukumbi, and Dr. Béatrice Ilunga of Amo-Congo, Democratic Republic of Congo; Dr. Marie-Thérèse Abena Obama and Dr. Nelly Kamgaing of Centre Hospitalier et Universitaire de Yaoundé, Yaoundé Cameroon; Dr. Wilfred Akam of Limbé Provincial Hospital, Limbé, Cameroon; Dr. Jean Lusiama of Kalembe Lembe Pediatric Hospital, Kinshasa, Democratic Republic of Congo; IeDEA Central Africa Regional offices: Mr. Joseph Atibu, Mr. Innocent Azinyue, Dr. John Ditekemena, Dr. Modeste Kiumbu, Mr. Christian Kondé, and Mr. Kashamuka Mwandagalirwa; and RTI International: Dr. Jamie Newman and Ms. Jennifer Hemingway-Foday.

The IeDEA East Africa Steering Group is organized as follows: Dr. S Ayaya: Academic Model Providing Access To Healthcare (AMPATH) Program; Dr. Lyamuya: Morogoro; Dr. Maruchu: Tumbi; Dr. Bukusi and Dr. Cohen: Family AIDS Care and Education Services (FACES); BS. Musick, C.T. Yiannoutsos, and E. Sang: East African Regional Data Center.

The IeDEA Southern Africa Steering Group is organized as follows
Member Sites (Sites denoted with an asterisk contributed data to this analysis):
*Benjamin Chi, Center for Infectious Disease Research in Zambia, Zambia; *Brian Eley, Red Cross Children's Hospital, Cape Town, South Africa; Geoff Fatti, Kheth'impilo; Matthew Fox, Themba Lethu Clinic, Johannesburg, South Africa; Christiane Fritz, SolidarMed Zimbabwe, Zimbabwe; *Janet Giddy, McCord Hospital, Durban, South Africa; Christopher Hoffmann, Aurum Institute for Health Research, South Africa; Kennedy Malisita, Queen Elizabeth Central Hospital, Blantyre, Malawi; Portia Mutevedzi, Hlabisa HIV Treatment and Care Programme, South Africa; Denis Naniche, Centro de Investigaçao em Saude de Manhiça, Mozambique; Sabrina Pestilli, SolidarMed Mozambique, Mozambique; *Sam Phiri, Lighthouse Clinic, Lilongwe, Malawi; *Hans Prozesky, Tygerberg Academic Hospital, Stellenbosch, South Africa; *Shobna Sawry, Wits Institute for Sexual Reproductive Health, HIV & Related Diseases, University of the Witwatersrand, Johannesburg, and Harriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital, Soweto, South Africa;*Kathryn Stinson, Khayelitsha ART Programme and Médecins Sans Frontières, Cape Town, South Africa; *Karl Technau, Empilweni Service and Research Unit, Rahima Moosa Mother and Child Hospital, University of the Witwatersrand, Johannesburg, South Africa; *Maureen Wellington, Newlands Clinic, Harare, Zimbabwe;*Robin Wood, Gugulethu and Masiphumelele ART Programmes and Desmond Tutu HIV Centre, Cape Town, South Africa. Principal Investigators: Matthias Egger, Institute of Social and Preventive Medicine, University of Bern, Switzerland; Mary-Ann Davies, School of Public Health and Family Medicine, University of Cape Town, South Africa.

The TREAT Asia Pediatric Network of IeDEA Asia-Pacific is organized as follows: CV Mean, V Saphonn*, S Sarun, National Centre for HIV/AIDS Dermatology and STDs and University of Health Sciences, Phnom Penh, Cambodia; V Ung*†, M Pok, Y Kdan, B Chan, University of Health Sciences and National Pediatric Hospital, Phnom Penh, Cambodia; J Tucker, New Hope for Cambodian Children, Phnom Penh, Cambodia; FJ Zhang, Beijing Ditan Hospital, Capital Medical University, Beijing, China; N Kumarasamy*, S Saghayam, E Chandrasekaran, YR Gaitonde Centre for AIDS Research and Education, Chennai, India; KDK Wati*, LPP Atmikasari, IY Malino, Sanglah Hospital, Udayana University, Bali, Indonesia; N Kurniati*, and D Muktiarti, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; SM Fong*, M Thien, M Lim, F Daut, Hospital Likas, Kota Kinabalu, Malaysia; NK Nik Yusoff*, P Mohamad , Hospital Raja Perempuan Zainab II, Kelantan, Malaysia; KA Razali *, TJ

Mohamed, NF Abdul Rahman, NADR Mohammed, Pediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; R Nallusamy*, KC Chan, Penang Hospital, Penang, Malaysia; V Sirisanthana*, P Oberdorfer, L Aurpibul, T Sudjaritruk, Research Institute for Health Sciences and Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; R Hansudewechakul*, S Denjunta, W Srisuk, A Kongphonoi, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; P Lumbiganon*, P Kosalaraksa, P Tharnprisan, T Udomphanit, Khon Kaen University, Khon Kaen, Thailand; G Jourdain, PHPT (IRD UMI 174 and Chiang Mai University), Chiang Mai, Thailand; T Bunupuradah*, T Puthanakit, W Prasitsuebsai, W Chanthaweethip, HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand; K Chokephaibulkit*, K Lapphra, W Phongsamart, S Sricharoenchai, Siriraj Hospital, Mahidol University, Bangkok, Thailand; KH Truong*‡, QT Du, and CH Nguyen, Children's Hospital 1, Ho Chi Minh City, Vietnam; VC Do*, TM Ha, AT Vu Children's Hospital 2, Ho Chi Minh City, Vietnam; LV Nguyen*, KDT Khu, AN Pham, LT Nguyen, National Hospital of Pediatrics, Hanoi, Vietnam; ON Le, Worldwide Orphans Foundation, Ho Chi Minh City, Vietnam; AH Sohn*, N Durier, C Sethaputra, TREAT Asia, amfAR -- The Foundation for AIDS Research, Bangkok, Thailand; DA Cooper, MG Law*, A Kariminia, The Kirby Institute, University of New South Wales, Sydney, Australia; (*Steering Committee members).

The IeDEA West Africa Collaboration Study Group (2006-2011) includes: Participating sites (*members of the **Steering Committee,** §members of the **Executive Committee**):
Benin, Cotonou: Adults: Djimon Marcel Zannou*, Carin Ahouada, Jocelyn Akakpo, Christelle Ahomadegbé, Jules Bashi, Alice Gougounon-Houéto, Angèle Azon-Kouanou, Fabien Houngbé, Jean Sehonou (CNHU Hubert Maga). Pediatrics: Sikiratou Koumakpaï*§, Florence Alihonou, Marcelline d'Almeida, Irvine Hodonou, Ghislaine Hounhoui, Gracien Sagbo, Leïla Tossa-Bagnan, Herman Adjide (CNHU Hubert Maga). ***Burkina Faso:*** Adults: Joseph Drabo*, René Bognounou, Arnaud Diendéré, Eliezer Traore, Lassane Zoungrana, Béatrice Zerbo (CHU Yalgado, ***Ouagadougou***), Adrien Bruno Sawadogo*§, Jacques Zoungrana, Arsène Héma, Ibrahim Soré, Guillaume Bado, Achille Tapsoba (CHU Souro Sanou, ***Bobo Dioulasso***) Pediatrics: Diarra Yé*, Fla Kouéta, Sylvie Ouedraogo, Rasmata Ouédraogo, William Hiembo, Mady Gansonré (CH Charles de Gaulle, ***Ouagadougou***). ***Côte d'Ivoire, Abidjan:*** Adults: Eugène Messou*, Joachim Charles Gnokoro, Mamadou Koné, Guillaume Martial Kouakou, (ACONDA-CePReF); Clarisse Amani Bosse*, Kouakou Brou, Achi Isidore Assi (ACONDA-MTCT-Plus); Henri Chenal*, Denise Hawerlander, Franck Soppi (CIRBA); Albert Minga*, Yao Abo, Jean-Michel Yoboue (CMSDS/CNTS); Serge Paul Eholié*§, Mensah Deborah Noelly Amego, Viviane Andavi, Zelica Diallo, Frédéric Ello, Aristophane Koffi Tanon (SMIT, CHU de Treichville), Serge Olivier Koule*, Koffi Charles Anzan, Calixte Guehi (USAC, CHU de Treichville). Pediatrics: Edmond Addi Aka*, Koffi Ladji Issouf, Jean-Claude Kouakou, Marie-Sylvie N'Gbeche, (ACONDA-CePReF); Touré Pety*, Divine Avit-Edi (ACONDA-MTCT-Plus); Kouadio Kouakou*, Magloire Moh, Valérie Andoblé Yao (CIRBA); Madeleine Amorissani Folquet*, Marie-Evelyne Dainguy, Cyrille Kouakou, Véronique Tanoh Méa-Assande, Gladys Oka-Berete, Nathalie Zobo, Patrick Acquah, Marie-Berthe Kokora (CHU Cocody); Tanoh François Eboua*, Marguerite Timité-Konan, Lucrèce Diecket Ahoussou, Julie Kebé Assouan, Mabéa Flora Sami, Clémence Kouadio (CHU Yopougon). ***Ghana, Accra:*** Pediatrics: Lorna Renner*§, Bamenla Goka, Jennifer Welbeck, Adziri Sackey, Seth Ntiri Owiafe (Korle Bu TH).
Guinea-Bissau: Adults: Christian Wejse*§, Zacarias José Da Silva*, Joao Paulo (Bandim Health Project), The Bissau HIV cohort study group: Amabelia Rodrigues (Bandim Health Project), David da Silva (National HIV program Bissau), Candida Medina (Hospital National Simao Mendes, Bissau), Ines Oliviera-Souto (Bandim Health Project), Lars Østergaard (Dept of Infectious Diseases, Aarhus University Hospital), Alex Laursen (Dept of Infectious Diseases, Aarhus University Hospital), Morten Sodemann (Dept of Infectious Diseases, Odense University Hospital), Peter Aaby (Bandim Health Project), Anders Fomsgaard (Dept. of Virology, Statens Serum Institut, Copenhagen), Christian Erikstrup (Dept. of Clinical Immunology), Jesper Eugen-Olsen (Dept. of Infectious Diseases, Hvidovre Hospital, Copenhagen). ***Mali, Bamako:*** Adults: Moussa Y Maïga*§, Fatoumata Fofana Diakité, Abdoulaye Kalle, Drissa Katile (CH Gabriel Toure), Hamar Alassane Traore*, Daouda Minta*,

Tidiani Cissé, Mamadou Dembelé, Mohammed Doumbia, Mahamadou Fomba, Assétou Soukho Kaya, Abdoulaye M Traoré, Hamady Traoré, Amadou Abathina Toure (CH Point G). Pediatrics: Fatoumata Dicko*, Mariam Sylla, Alima Berthé, Hadizatou Coulibaly Traoré, Anta Koïta, Niaboula Koné, Clémentine N'Diaye, Safiatou Touré Coulibaly, Mamadou Traoré, Naïchata Traoré (CH Gabriel Toure). ***Nigeria:*** Adults: Man Charurat* (UMB/IHV), Samuel Ajayi*, Georgina Alim, Stephen Dapiap, Otu (UATH, ***Abuja***), Festus Igbinoba (National Hospital ***Abuja***), Okwara Benson*, Clément Adebamowo*, Jesse James, Obaseki, Philip Osakede (UBTH, ***Benin City***), John Olasode (OATH, ***Ile-Ife***). ***Senegal, Dakar:*** Adults: Moussa Seydi*, Papa Salif Sow, Bernard Diop, Noël Magloire Manga, Judicael Malick Tine[§], Coumba Cissé Bassabi (SMIT, CHU Fann). Pediatrics: Haby Signate Sy*, Abou Ba, Aida Diagne, Hélène Dior, Malick Faye, Ramatoulaye Diagne Gueye, Aminata Diack Mbaye (CH Albert Royer). ***Togo, Lomé:*** Adults: Akessiwe Patassi*, Awèrou Kotosso, Benjamin Goilibe Kariyare, Gafarou Gbadamassi, Agbo Komi, Kankoé Edem Mensah-Zukong, Pinuwe Pakpame (CHU Tokoin/Sylvanus Olympio). Pediatrics: Annette Koko Lawson-Evi*[§], Yawo Atakouma, Elom Takassi, Améyo Djeha, Ayoko Ephoévi-gah, Sherifa El-Hadj Djibril (CHU Tokoin/Sylvanus Olympio). **Executive Committee*:** François Dabis (Principal Investigator, Bordeaux, France), Emmanuel Bissagnene (Co-Principal Investigator, Abidjan, Côte d'Ivoire), Elise Arrivé (Bordeaux, France), Patrick Coffie (Abidjan, Côte d'Ivoire), Didier Ekouevi (Abidjan, Côte d'Ivoire), Antoine Jaquet (Bordeaux, France), Valériane Leroy (Bordeaux, France), Charlotte Lewden (Bordeaux, France), Annie Sasco (Bordeaux, France). **Operational and Statistical Team:** Dieudonné Amani (Abidjan, Côte d'Ivoire), Jean-Claude Azani (Abidjan, Côte d'Ivoire), Eric Balestre (Bordeaux, France), Serge Bessekon (Abidjan, Côte d'Ivoire), Franck Bohossou (Abidjan, Côte d'Ivoire), Camille Gilbert (Bordeaux, France), Sophie Karcher (Bordeaux, France), Jules Mahan Gonsan (Abidjan, Côte d'Ivoire), Jérôme Le Carrou (Bordeaux, France), Séverin Lenaud (Abidjan, Côte d'Ivoire), Célestin Nchot (Abidjan, Côte d'Ivoire), Karen Malateste (Bordeaux, France), Amon Roseamonde Yao (Abidjan, Côte d'Ivoire), Bertine Siloué (Abidjan, Côte d'Ivoire). **Administrative Team:** Gwenaelle Clouet (Bordeaux, France), Madikona Dosso (Abidjan, Côte d'Ivoire), Alexandra Doring[§] (Bordeaux, France), Adrienne Kouakou (Abidjan, Côte d'Ivoire), Elodie Rabourdin (Bordeaux, France), Jean Rivenc (Pessac, France). **Consultants/ Working Groups:** Xavier Anglaret (Bordeaux, France), Boubacar Ba (Bamako, Mali), Jean Bosco Essanin (Abidjan), Andrea Ciaranello (Boston, USA), Sébastien Datté (Abidjan, Côte d'Ivoire), Sophie Desmonde (Bordeaux, France), Jean-Serge Elvis Diby (Abidjan, Côte d'Ivoire), Geoffrey S.Gottlieb* (Seattle, USA), Apollinaire Gninlgninrin Horo (Abidjan, Côte d'Ivoire), Serge N'zoré Kangah (Abidjan, Côte d'Ivoire), Denis Malvy (Bordeaux, France), David Meless (Abidjan, Côte d'Ivoire) , Aida Mounkaila-Harouna (Bordeaux, France), Camille Ndondoki (Bordeaux, France), Caroline Shiboski (San Francisco USA), Rodolphe Thiébaut (Bordeaux, France).
Coordinating Centre: ISPED, Univ Bordeaux Segalen, Bordeaux, France. **Regional Office:** PAC-CI, Abidjan, Côte d'Ivoire. **Methodologic Support**: MEREVA, Bordeaux, France
Website: http://www.mereva.net/iedea